The Next SuperStar Drug? AbbVie Places its Hope on Skyrizi and Rinvoq
AbbVie has published its financial report recently, showing that its top-selling drug Humira, known as adalimumab, has made great sales again at USD 20.7 billion. Humira has been the best-selling monoclonal antibody drug of AbbVie since marketing, however, is going to lose the protection from patent regulation in 2023. Pharmaceutical companies with biosimilar molecule drugs are expected to join the fierce competition, including Amgen, Samsung, Boehringer Ingelheim, Mylan, Novartis, and Pfizer.
GO Prime with only $1.49 now
LATEST
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115